Search
for
Sort by
Research 421–450 of 1000+
- ALOPECIA AREATA: ASPECTOS FISIOLÓGICOS E AVANÇOS TERAPÊUTICOS – UMA REVISÃO DE LITERATURA
- Treatment of Lichen Planopilaris and Frontal Fibrosing Alopecia: A Retrospective, Real-Life Analysis in a Tertiary Center in Germany
- Alopecia Universalis with Frequently Relapsing Nephrotic Syndrome of Infantile Onset: A Rare Presentation
- Treatment of Crohn's Disease and Concomitant Alopecia Areata With Tofacitinib
- Central centrifugal cicatricial alopecia: retrospective case-control study of 54 patients from a tertiary care center
- Efficacy and safety of ritlecitinib in adults and adolescents with alopecia areata: a randomised, double-blind, multicentre, phase 2b–3 trial
- The Role of Tofacitinib in the Management of Alopecia Totalis
- Recent Advances in Understanding of the Etiopathogenesis, Diagnosis, and Management of Hair Loss Diseases
- The JAK/STAT signaling pathway: from bench to clinic
- SOCS1 and SOCS3 as key checkpoint molecules in the immune responses associated to skin inflammation and malignant transformation
- PKC downregulation upon rapamycin treatment attenuates mitochondrial disease
- SnapshotDx Quiz: February 2018
- Management of folliculitis decalvans: The EADV task force on hair diseases position statement
- Treatment of Frontal Fibrosing Alopecia and Lichen Planopilaris
- Valproic Acid Induces Hair Regeneration in Murine Model and Activates Alkaline Phosphatase Activity in Human Dermal Papilla Cells
- Combination of baricitinib and conventional immunomodulating therapy for alopecia totalis
- Drug-Induced Hair Loss: Analysis of the Food and Drug Administration’s Adverse Events Reporting System Database
- Effectiveness of Baricitinib on Nail Alopecia Areata: A 48-Week Single-Center Retrospective Study
- Poster Presentations at the 28th Joint Meeting of the International Society of Dermatopathology, March 5–6, 2025, Orlando, Florida, USA
- Real-World Experience of Tofacitinib and Baricitinib Use in Alopecia Areata in Greek Population: A Retrospective Analysis With Focus on Safety
- A Phase 1, Open‐Label Study of the Pharmacokinetics of Ritlecitinib in Children Aged 6–12 Years With Alopecia Areata
- La FDA aprueba Litfulo® (ritlecitinib) para el tratamiento de la alopecia areata grave en adolescentes y adultos
- TYK2 Inhibition with Deucravacitinib Improves Clinical Outcomes and Resolves Interferon-Driven Inflammation in Lichen Planopilaris
- Tofacitinib: The selected selective JAK inhibitor in paediatric dermatology
- Small Molecule Inhibitors and Inflammatory Skin Diseases
- Alopecia Areata: a Comprehensive Review of Pathogenesis and Management
- Teriflunomide: a novel oral treatment for relapsing multiple sclerosis
- Clinical Outcomes of Ritlecitinib in Treatment-Refractory Alopecia Areata: A Single-Center Real-World Study
- <i>In Vitro</i> and <i>In Vivo</i> Models for the Development of Hair Growth Materials By Regulating the <i>β</i>-Catenin Signaling Pathways
- JAK inhibition in the treatment of alopecia areata – a promising new dawn?